Last reviewed · How we verify
Conventional DAPT
Conventional DAPT (Dual Antiplatelet Therapy) combines two antiplatelet agents to inhibit platelet aggregation through different pathways, reducing thrombotic events.
Conventional DAPT (Dual Antiplatelet Therapy) combines two antiplatelet agents to inhibit platelet aggregation through different pathways, reducing thrombotic events. Used for Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI), Secondary prevention of stent thrombosis post-PCI, Stable coronary artery disease with stent placement.
At a glance
| Generic name | Conventional DAPT |
|---|---|
| Also known as | Unguided DAPT |
| Sponsor | Zunyi Medical College |
| Drug class | Antiplatelet combination therapy |
| Target | Cyclooxygenase (COX) and P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
DAPT typically combines aspirin (which inhibits cyclooxygenase and thromboxane A2 production) with a P2Y12 receptor antagonist (such as clopidogrel, prasugrel, or ticagrelor) to provide complementary antiplatelet effects. This dual mechanism prevents platelet activation and aggregation more effectively than monotherapy, reducing the risk of stent thrombosis and recurrent ischemic events in cardiovascular patients.
Approved indications
- Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI)
- Secondary prevention of stent thrombosis post-PCI
- Stable coronary artery disease with stent placement
Common side effects
- Bleeding (major and minor)
- Gastrointestinal bleeding
- Dyspepsia
- Bruising
- Thrombotic thrombocytopenic purpura (TTP)
Key clinical trials
- STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT (NA)
- Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk (NA)
- Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM) (NA)
- Ticagrelor De-escalation Strategy in AMI Patients (PHASE4)
- The Study of CYP2C19 Genotype-Guided Clopidogrel Treatment Models (NA)
- CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 4 (PHASE4)
- Comparison of Short Versus 12 Months Prasugrel Plus Aspirin in Patients with Acute Coronary Syndromes Treated with Percutaneous Coronary Intervention and Everolimus-eluting Stents (PHASE4)
- Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Conventional DAPT CI brief — competitive landscape report
- Conventional DAPT updates RSS · CI watch RSS
- Zunyi Medical College portfolio CI